Search Results
May 27, 2026, 08:37 ET Preservation Equity Fund Advisors and Freestone Capital Form Joint Venture to Preserve Affordable Housing Assets
multimedia:https://www.prnewswire.com/news-releases/preservation-equity-fund-advisors-and-freestone-capital-form-joint-venture-to-preserve-affordable-housing-assets-302782768.htmlSOURCE
More news about: PEF Advisors
May 27, 2026, 08:34 ET X-Bow® Reaches Milestone in Technology Development for Expansion of U.S. Solid Rocket Motor Production Capacity
X-Bow's innovation is its patented Additive Manufacturing of Solid Propellant (AMSP) process, now realized at industrial scale through Gen-0 and in mobile form through Rocket Factory in a Box (RFIB™). Gen-0 represents X-Bow's flagship high-volume manufacturing system, supporting contested logistics, hypersonics,
More news about: X-Bow Systems
May 27, 2026, 08:31 ET BMNT Names Brian Miller President as Firm Scales Its Role Across the Government Innovation Ecosystem
ecosystem connectivity that make that possible without losing the rigor and judgment BMNT is known for."The promotions of Petkosek and Donoghue form a four-person Director group responsible for the standards, cadence, and cross-functional execution that allow BMNT to deliver consistently as the firm
More news about: BMNT
May 27, 2026, 08:31 ET MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking
More news about: MetaVia Inc.
May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
cases but is responsible for nearly 90% of central vision loss linked to the disease. In contrast, around 80% of patients have the non-neovascular form; however, it is the neovascular type that leads to the vast majority of severe central vision impairment associated with AMD.Wet AMD Epidemiology
More news about: DelveInsight Business Research, LLP
May 27, 2026, 08:30 ET Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.Forward-looking statements are presented as of the date of this press release. Except as required by law,
More news about: Atossa Therapeutics Inc
May 27, 2026, 08:30 ET IAB Tech Lab Releases Guidance On AI System Bot Management Strategies For Public Comment
visibility into how their content is accessed and used. TwelveLabs is proud to contribute as this work is foundational to ensuring video, the richest form of data, is no longer overlooked in how AI engages with the web." The guidance was developed by the CoMP Working Group, with public comment
More news about: IAB Tech Lab
May 27, 2026, 08:30 ET ROLLINS, INC. ANNOUNCES CFO TRANSITION
implied by forward-looking statements including, but not limited to, those set forth in the sections entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and may also be described from time to time in our future reports filed with the SEC.Accordingly,
More news about: Rollins, Inc.
May 27, 2026, 08:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current
More news about: VolitionRx Limited
May 27, 2026, 08:11 ET Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
factors are described in the Company's filings with the Securities and Exchange Commission ("SEC") including the Company's most recent Annual Report on Form 10-K and the Company's other filings made with the SEC. Although the Company believes that the expectations reflected in the forward-looking statements
More news about: Hoth Therapeutics, Inc.
May 27, 2026, 08:04 ET TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode
More news about: TransCode Therapeutics, Inc.
May 27, 2026, 08:02 ET Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
(iDFU). The gel formulation of the topically applied Nu-3 is designed specifically to adhere to wounds and comprises lyotropic liquid crystals that form a mobile network through hydrogen bonding to water."These newly issued patents further strengthen and expand our global intellectual property
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 27, 2026, 08:00 ET Verge Labs Launches as a Frontier AI Lab for Human Disease Biology
first AI-discovered asset completed a Phase 1b in late 2025. The trial's clinical, biomarker, and patient data have now been folded into VergeDB and form a core training signal for their models. Verge Labs is publishing a
More news about: Verge Labs
May 27, 2026, 08:00 ET Q32 Bio Announces $55 Million Private Placement Financing
forward-looking information include, among others, the factors discussed throughout the "Risk Factors" section of the Company's most recently Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission, and subsequent quarterly reports. Except as required
More news about: Q32 Bio
May 27, 2026, 08:00 ET As Federal Definition of Ultra-Processed Foods Stalls, Yuka Releases Landmark Report Mapping the System Behind America's Diet-Related Health Crisis
policies that have already been implemented in other countries. Chile, Peru, Argentina, Mexico, Portugal, and the United Kingdom have all adopted some form of UPF marketing restriction or front-of-pack warning labeling with measurable results. In Chile, three years after the introduction of mandatory warning
More news about: Yuca Corp
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
2026.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic
More news about: Nuvation Bio Inc.
May 27, 2026, 07:30 ET Einride Teams up with TÜV SÜD for Independent Verification of First Autonomous Safety Management Governance Framework
a definitive business combination agreement (the "Transaction"). The Transaction is expected to result in Einride listing its ordinary shares in the form of American Depositary Shares ("ADS") on NASDAQ in the second quarter of 2026 under the ticker symbol "ENRD", subject to customary closing conditions. About
More news about: Einride
May 27, 2026, 07:27 ET Einride Teams up with TÜV SÜD for Independent Verification of First Autonomous Safety Management Governance Framework
a definitive business combination agreement (the "Transaction"). The Transaction is expected to result in Einride listing its ordinary shares in the form of American Depositary Shares ("ADS") on NASDAQ in the second quarter of 2026 under the ticker symbol "ENRD", subject to customary closing conditions. About
More news about: Einride
May 27, 2026, 07:11 ET iQIYI's AI Platform Nadou Pro Surpasses 10,000 Creators, Unveils Advanced Feature Updates and Global Expansion
creator base spans traditional production companies and independent filmmakers, with active projects across every major content format: long-form dramas, short-form dramas, online feature films, short dramas, micro animations, and advertising. The breadth of partners and formats reflects the platform's
More news about: iQIYI
May 27, 2026, 07:03 ET Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development
There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find
More news about: Veeva Systems
May 27, 2026, 07:03 ET Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide
There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find
More news about: Veeva Systems
May 27, 2026, 07:03 ET Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development
There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find
More news about: Veeva Systems
May 27, 2026, 07:03 ET Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide
There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find
More news about: Veeva Systems
May 27, 2026, 07:00 ET Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
and Analysis of Financial Condition and Results of Operations" in Vanda's most recent Annual Report on Form 10‑K, as updated by Vanda's subsequent Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K, and other filings with the U.S. Securities and Exchange Commission, which are available at
More news about: Vanda Pharmaceuticals Inc.
May 27, 2026, 07:00 ET Z Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes
Factors" in the Company's Registration Statement on Form S-4 (File No. 333-288329) and in the Company's other filings with the U.S. Securities and Exchange Commission, including its most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at
More news about: Z Squared Inc.